No worries, I enjoy writing....I did make another small change, adding in that BETonMACE's patient population suffers from Diabetes:

As noted earlier, the primary end point of the BETonMACE trial is not Alzheimer's or Vascular Dementia.  The primary end point is about measuring the time to first occurrence of a Major Adverse Cardiac Event, or MACE for short in patients with Diabetes Mellitus.